IVVD

Rating neutralAI Memo

Invivyd

As of 2026-08-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

DECLARATION/VYD2311 Q3 2026 topline readout • 2026-09-30

Base target: $1 / p=45% prob

Biggest risk

The downside case is dominated by binary clinical efficacy and timing risk, uncertain future COVID demand, elevated clinical spending, and the Nasdaq bid-price deficiency. Analyst revisions and consensus surprise data are unavailable.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The positive case rests on an on-track pivotal VYD2311 program, Q3 2026 topline data, the planned LIBERTY follow-on study, continued PEMGARDA revenue growth, and cash support for trial and launch preparation.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-06

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

PEMGARDA revenue and balance-sheet support
LIBERTY VYD2311 head-to-head and combination study
The positive case rests on an on-track pivotal VYD2311 program, Q3 2026 topline data, the planned LIBERTY follow-on study, continued PEMGARDA revenue growth, and cash support for trial and launch preparation.

BearKey bullets

Analyst target revisions, consensus estimates, options data, short interest, and social sentiment are unavailable.
DECLARATION topline results could disappoint, be delayed, or fail to support approval.
Elevated VYD2311 clinical spending and ATM financing make cash consumption and potential dilution important monitoring items.

WatchKey bullets

DECLARATION/VYD2311 Q3 2026 topline readout

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=45%)

Target spread vs base: +69% / -56%

Scenario probabilities

Bull Target: $1 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

Recent coverage is mixed: clinical progress and PEMGARDA growth are supportive, while the Nasdaq deficiency is a material negative overhang. Social, options, short-interest, employee-review, and analyst-revision data are unavailable; zero values in those fields indicate missing data, not neutral evidence. This remains a cautious, event-driven monitoring setup.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

PEMGARDA revenue and balance-sheet support
LIBERTY VYD2311 head-to-head and combination study

Scenarios

Bull Target (Scenario probability)

$1 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
DECLARATION/VYD2311 Q3 2026 topline readout
Invivyd says top-line data from the pivotal DECLARATION trial is anticipated in Q3 2026; the exact date is undisclosed. The readout remains highly binary. [#SEC-8K-2026-05-14]
Prob 65.00% • Move 85.00% • Priced-in 25.00%
EVENT2027-01-19
Nasdaq minimum-bid remediation
Nasdaq notified Invivyd that its stock had closed below the $1 minimum bid requirement for 30 consecutive business days. The initial compliance deadline is January 19, 2027; failure to cure could lead to further review and possible delisting, with no assurance of compliance. [#8-K-2026-07-24]
Prob 60.00% • Move -25.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

PEMGARDA revenue and balance-sheet support
2026-08-31
Q1 PEMGARDA net product revenue was $13.7 million, up 22% year over year. Q1 cash was $184.2 million, with approximately $20 million of additional gross ATM proceeds in April; major VYD2311 clinical spending was expected to end later in the summer. [#SEC-8K-2026-05-14]
Prob 70% • Move 15% • Priced-in 45%
LIBERTY VYD2311 head-to-head and combination study
2027-08-06
Invivyd said the LIBERTY head-to-head safety and combination study of VYD2311 versus an mRNA COVID vaccine was planned to begin shortly, providing a distinct follow-on program milestone beyond DECLARATION. The start date remains undisclosed. [#SEC-8K-2026-05-14]
Prob 55% • Move 20% • Priced-in 20%

Risks

Analyst target revisions, consensus estimates, options data, short interest, and social sentiment are unavailable.
DECLARATION topline results could disappoint, be delayed, or fail to support approval.
Elevated VYD2311 clinical spending and ATM financing make cash consumption and potential dilution important monitoring items.
PEMGARDA demand may remain seasonal and sensitive to changing COVID activity, variant dynamics, and regulatory conditions.
The company may not regain Nasdaq's $1 minimum-bid requirement by January 19, 2027, creating delisting or capital-structure risk. [#8-K-2026-07-24]

Peers

Symbol	Summary
ARCT	Same-sector small-cap biotech near IVVD's market-cap band; the packet does not establish indication or program overlap, so comparison is limited.
CRBP	Same-sector small-cap biotech near IVVD's market-cap band; no direct clinical or commercial comparability is established.
TNXP	Same-sector small-cap biotech near IVVD's market-cap band; useful only as broad size and sector context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

ARCT

Same-sector small-cap biotech near IVVD's market-cap band; the packet does not establish indication or program overlap, so comparison is limited.

CRBP

Same-sector small-cap biotech near IVVD's market-cap band; no direct clinical or commercial comparability is established.

TNXP

Same-sector small-cap biotech near IVVD's market-cap band; useful only as broad size and sector context.